Early translational study supports the role of high-dose inhaled nitric oxide as a potential antimicrobial therapy
Researchers report that high-dose inhaled nitric oxide (iNO) demonstrates potential antimicrobial activity in preclinical models and is safe and feasible in early human studies, supporting further clinical investigation.
Registered users, subscribers or members - SIGN IN
To continue reading this article
Membership
Included as a benefit
Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.
Find out more about how to join.
Register
FREE
Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.
Subscribe
3.75 per month / £35 annually
Get unlimited access to The Microbiologist.